Bosh sahifaIVBIY • OTCMKTS
add
Innovent Biologics ADR Representing 4 Ord Shs
Yopilish kursi
39,75 $
Yillik diapazon
22,29 $ - 52,00 $
Bozor kapitalizatsiyasi
157,45 mlrd HKD
Oʻrtacha hajm
4,00
Narx/foyda
-
Dividend daromadliligi
-
Bozor yangiliklari
MarketWatch
1 kun oldin
The S&P 500 is undergoing a historic shift that could reshape the stock market
0,69%
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (CNY) | iyn, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 2,98 mlrd | 50,62% |
Joriy xarajat | 1,91 mlrd | 16,28% |
Sof foyda | 417,16 mln | 312,50% |
Sof foyda marjasi | 14,01 | 241,09% |
Har bir ulushga tushum | — | — |
EBITDA | 514,79 mln | 513,71% |
Amaldagi soliq stavkasi | 7,00% | — |
Balans
Jami aktivlari
Jami passivlari
| (CNY) | iyn, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 9,54 mlrd | 10,56% |
Jami aktivlari | 23,59 mlrd | 16,25% |
Jami passivlari | 9,17 mlrd | 16,56% |
Umumiy kapital | 14,42 mlrd | — |
Tarqatilgan aksiyalar | 1,65 mlrd | — |
Narxi/balansdagi bahosi | 4,56 | — |
Aktivlardan daromad | 4,10% | — |
Kapitaldan daromad | 5,43% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (CNY) | iyn, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 417,16 mln | 312,50% |
Operatsiyalardan naqd pul | 156,88 mln | 245,51% |
Sarmoyadan naqd pul | 272,40 mln | 198,39% |
Moliyadan naqd pul | 324,21 mln | 348,61% |
Naqd pulning sof oʻzgarishi | 748,48 mln | 245,09% |
Boʻsh pul | 377,17 mln | 233,09% |
Haqida
Innovent Biologics, Inc. is a publicly listed Chinese biopharmaceutical company that is headquartered in Suzhou, Jiangsu. Wikipedia
CEO
Tashkil etilgan
28-noy, 2011
Sayt
Xodimlar soni
6 190
